ロード中...
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Lasmiditan, a serotonin 5-HT(1F) receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those wi...
保存先:
| 出版年: | Brain |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6620826/ https://ncbi.nlm.nih.gov/pubmed/31132795 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awz134 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|